Literature DB >> 2882613

Advances in the diagnosis and treatment of medullary thyroid carcinoma.

L M Brunt, S A Wells.   

Abstract

Medullary thyroid carcinoma accounts for 5 to 10 per cent of all thyroid malignancies and may occur in a familial or a sporadic pattern. This article reviews the authors' experience with 200 patients with medullary thyroid carcinoma and outlines the recent advances made in our understanding of the biochemical properties of these cancer cells and the relationship of different tumor markers to prognosis.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2882613     DOI： 10.1016/s0039-6109(16)44183-6

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN： 0039-6109            Impact factor:   2.741


  15 in total

1.  Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.

Authors:  Elaine T Lam; Matthew D Ringel; Richard T Kloos; Thomas W Prior; Michael V Knopp; Jiachao Liang; Steffen Sammet; Nathan C Hall; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Pamela J Snyder; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Jeffrey F Moley; Miguel A Villalona-Calero; Manisha H Shah
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

2.  Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.

Authors:  J A van Heerden; C S Grant; H Gharib; I D Hay; D M Ilstrup
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

3.  Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer.

Authors:  Mackenzie Cook; Xiao-Min Yu; Herbert Chen
Journal:  Am J Transl Res       Date:  2010-02-10       Impact factor: 4.060

4.  Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma.

Authors:  N Neuhold; F Längle; M Gnant; U Hollenstein; B Niederle
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 5.  Medullary thyroid carcinoma and multiple endocrine neoplasia type 2.

Authors:  Hiroshi Takami
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

6.  Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma.

Authors:  H Dralle; I Damm; G F Scheumann; J Kotzerke; E Kupsch; H Geerlings; R Pichlmayr
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

7.  Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid.

Authors:  O Ugur; L Kostakğlu; N Güler; B Caner; U Uysal; N Elahi; M Haliloğlu; D Yüksel; T Aras; H Bayhan; C Bekdik
Journal:  Eur J Nucl Med       Date:  1996-10

8.  Pre- and postoperative carcinoembryonic antigen determinations in hepatic resection for colorectal metastases. Predictive value and implications for adjuvant treatment based on multivariate analysis.

Authors:  P Hohenberger; P M Schlag; T Gerneth; C Herfarth
Journal:  Ann Surg       Date:  1994-02       Impact factor: 12.969

9.  Treatment of medullary carcinoma of the thyroid by laryngo-pharyngo-oesophagectomy--a case report.

Authors:  S Pender; D M Little; P Burke; P Broe
Journal:  Ir J Med Sci       Date:  1992-07       Impact factor: 1.568

10.  Presymptomatic screening for medullary thyroid carcinoma in patients with multiple endocrine neoplasia type 2A.

Authors:  A Frilling; H D Röher; B A Ponder
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.